This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
Participants willing and able to provide informed consent
Participants on inhaled treprostinil
Idiopathic interstitial pneumonia (IIP)
Chronic hypersensitivity pneumonitis
Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).
Exacerbation of underlying lung disease within 28 days prior to randomization.
Initiation of pulmonary rehabilitation within 28 days prior to randomization.
Receiving >10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
Single group
inhaled mosliciguat
DrugDose level 1, 2, or 3 for inhalation
Dry Powder Inhaler
DeviceDry powder inhaler for mosliciguat delivery
Incidence and nature of participant TEAEs, SAEs, and AEs leading to discontinuation
Click on the lead sponsor to view all of their trials.
